- Home
- MDXG vs OCS Comparison
MDXG vs OCS Comparison
Compare MDXG & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDXG
- OCS
- Stock Information
- Founded
- MDXG 2006
- OCS 2003
- Country
- MDXG United States
- OCS Switzerland
- Employees
- MDXG N/A
- OCS N/A
- Industry
- MDXG Biotechnology: Pharmaceutical Preparations
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- MDXG Health Care
- OCS Health Care
- Exchange
- MDXG Nasdaq
- OCS Nasdaq
- Market Cap
- MDXG 1.1B
- OCS 956.4M
- IPO Year
- MDXG N/A
- OCS N/A
- Fundamental
- Price
- MDXG $7.14
- OCS $17.22
- Analyst Decision
- MDXG Buy
- OCS Strong Buy
- Analyst Count
- MDXG 1
- OCS 4
- Target Price
- MDXG $12.00
- OCS $35.75
- AVG Volume (30 Days)
- MDXG 466.3K
- OCS 11.7K
- Earning Date
- MDXG 10-29-2025
- OCS 08-21-2025
- Dividend Yield
- MDXG N/A
- OCS N/A
- EPS Growth
- MDXG N/A
- OCS N/A
- EPS
- MDXG 0.21
- OCS N/A
- Revenue
- MDXG $363,774,000.00
- OCS $960,668.00
- Revenue This Year
- MDXG $12.68
- OCS $11.49
- Revenue Next Year
- MDXG $8.18
- OCS $1,784.02
- P/E Ratio
- MDXG $33.98
- OCS N/A
- Revenue Growth
- MDXG 6.85
- OCS N/A
- 52 Week Low
- MDXG $5.47
- OCS $11.56
- 52 Week High
- MDXG $10.14
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- MDXG 53.02
- OCS 46.48
- Support Level
- MDXG $6.98
- OCS $16.00
- Resistance Level
- MDXG $7.23
- OCS $16.60
- Average True Range (ATR)
- MDXG 0.18
- OCS 0.42
- MACD
- MDXG -0.03
- OCS -0.04
- Stochastic Oscillator
- MDXG 39.02
- OCS 54.71
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.